Dyadic International, Inc. Announces Appointment of Barry Buckland to its Board of Directors
January 02, 2018
Share
Dyadic International, Inc. announced the appointment of Barry Buckland, Ph.D., to its Board of Directors, effective January 3, 2018. Dr. Buckland spent 29 years at Merck where he served in a number of senior R&D leadership roles. His last position was serving as Vice President Bioprocess R&D,
Merck Research Laboratories focusing on fermentation and bioprocess development and the commercial manufacturing of biologics. Currently, Dr. Buckland is the Executive Director, NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals). In addition, Dr. Buckland also serves as a consultant and on Scientific Advisory Boards at various companies and institutions.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
DYADIC INTERNATIONAL, INC. 
